ArticleArchives of toxicology2026
Mapping 3Rs and NAM research and innovation projects funded through European framework programmes since 2007.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The development of new approach methodologies (NAMs) is increasingly enabling the replacement and reduction of animal use in research, complementing the ethical framework provided by the 3Rs (replacement, refinement, and reduction) of animal research. The European Commission has supported these approaches by embedding 3R requirements in policy frameworks and providing dedicated funding for 3Rs/NAMs-related research. However, a systematic and comprehensive overview on European Union (EU) research funding of these projects is lacking. In this study, projects funded under Framework Programme 7 (2007-2013), Horizon 2020 (2014-2020) and Horizon Europe (2021-2027, extracted until March 2025) were analysed using the EU Community Research and Development Information Service database (CORDIS). A 2-tiered artificial intelligence-based data retrieval approach was applied, combining supervised text classification and semantic search followed by expert review, yielding a total of 539 relevant projects. Approximately 40% of these projects were toxicology-related, while the remainder pertained to areas such as disease research or technology scaling. Across the portfolio, oncology and neuroscience emerged as major application areas, with a strong representation of in vitro methodologies, including 3D cell culture methods and engineered models such as organs-on-chip, alongside in silico technologies. In terms of country participation and collaboration, Western European countries occupied central positions in obtaining funding and leading research efforts in this field. Overall, these findings demonstrate that EU framework programmes have provided substantial and sustained support for 3Rs/NAMs research and innovation, while also highlighting thematic and geographic imbalances that can inform future research and policy initiatives.
Indexed as
Identifiers
41984093What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.